Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Successful live birth following immunomodulatory therapy in a patient with multiple recurrent pregnancy loss and massive perivillous fibrinoid deposition.

Journal of reproductive immunology·2026

Same author

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.

Journal of autoimmunity·2026

Same author

Does daptomycin still have a part to play in the treatment of Enterococcus faecium bacteremia in the intensive care unit?

Critical care (London, England)·2026

Same author

[Streamlining laboratory tests in an internal medicine department: Economic and environmental benefits].

La Revue de medecine interne·2026

Same author

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.

Journal of autoimmunity·2026

Same author

Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.

PloS one·2026

Same journal

Innate immune recognition of <i>Bartonella bacilliformis</i>: TLR2/TLR4 expression and cytokine modulation.

Innate immunity·2026

Same journal

Trained immunity agonists given to neonatal mice fail to protect against leptospiral infection in adulthood and may cause adverse effects.

Innate immunity·2026

Same journal

Tn-Glycoconjugates engage MGL2 to potentiate TLR9-mediated dendritic cell maturation and Th1-skewed immune responses.

Innate immunity·2026

Same journal

Advancing lupus nephritis research through multi-omics and predictive modeling.

Innate immunity·2026

Same journal

The role of trained immunity in chronic non-communicable inflammatory diseases.

Innate immunity·2026

Same journal

Endothelial progenitor cell numbers vary in newborns and adults; anti-gm-CSFα (CD116) antibody as a novel marker for EPC enumeration.

Innate immunity·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients:

Tomas Urbina^1,2, Jean-Rémi Lavillegrand^1,2, Marc Garnier^2,3

¹Service de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.

Innate Immunity

|January 28, 2022

Summary

This summary is machine-generated.

Tocilizumab treatment in critically-ill SARS-CoV-2 pneumonia patients was associated with higher IL-6 and lower C-reactive protein and fibrinogen. Non-survivors showed a delayed decrease in these inflammatory biomarkers.

Keywords:

C-reactive protein SARS-CoV-2 Tocilizumab cytokine intensive care unit

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Related Experiment Videos

Last Updated: Oct 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Area of Science:

Critical Care Medicine
Immunology
Virology

Background:

Limited understanding of Tocilizumab's immuno-inflammatory effects in severe SARS-CoV-2 pneumonia.
Investigating the association between Tocilizumab treatment and patient outcomes in intensive care settings.

Purpose of the Study:

To analyze the immuno-inflammatory response to Tocilizumab in critically-ill SARS-CoV-2 patients.
To determine the relationship between Tocilizumab, inflammatory markers, and patient outcomes.

Main Methods:

Multicenter retrospective cohort study of 21 Tocilizumab-treated and 42 non-treated SARS-CoV-2 patients.
Matched patients based on gender and SAPS II score.
Collected IL-6, C-reactive protein, and fibrinogen levels at multiple time points (T1, T2, T3).

Main Results:

Tocilizumab-treated patients exhibited persistently higher IL-6 and lower C-reactive protein and fibrinogen levels.
No difference in baseline inflammatory biomarkers was observed between survivors and non-survivors among Tocilizumab-treated patients.
Non-survivors demonstrated a delayed decrease in C-reactive protein and fibrinogen levels compared to survivors.

Conclusions:

Tocilizumab treatment is linked to sustained elevated IL-6 and reduced C-reactive protein and fibrinogen in severe SARS-CoV-2 pneumonia.
Delayed reduction in inflammatory markers in Tocilizumab-treated patients indicates a poorer prognosis.